Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 47

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 47
---
,000 shares of its common stock in a registered direct offering in exchange for gross proceeds of $18.9 million (net proceeds
of $17.4 million).

During
the six months ended June 30, 2024, the Company sold 198,364 shares of its common stock under its ATM program for net proceeds of approximately
$2.0 million.

During
the six months ended June 30, 2024, the Company sold 1,557,692 shares of its common stock and 1,557,592 warrants to purchase its common
stock for net proceeds of $13.5 million.

During
the six months ended June 30, 2024, the Company repaid $5.0 million of its debt.

Critical Accounting Estimates

Our discussion and analysis
of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have
been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. Actual results
may differ from these estimates. Our critical accounting estimates are discussed in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2024, and there have been no material changes during the six months ended June 30, 2025.

34

Item 3. Quantitative
and Qualitative Disclosures About Market Risk

Pursuant to Item 305(e) of
Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller
reporting company,” as defined by Rule 229.10(f)(1). 

Item 4. Controls
and Procedures

Evaluation of Disclosure Controls and Procedures

Our
management, with the participation of our Principal Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) at the end of the period covered by this quarterly report.

Based
on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance
that the information required to be disclosed by us in the reports we file or submit under the Exchange Act